Augmented Toll-like receptor 4 (TLR4) expression was found in nearly 70% of patients with pancreatic adenocarcinoma, which is correlated with increased tumorigenesis and progression. This evidence concerns the gene TLR4 and pancreatic adenocarcinoma.